$GYHT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HALOZYME THERAPEUTICS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HALOZYME THERAPEUTICS, INC.. Get notifications about new insider transactions in HALOZYME THERAPEUTICS, INC. for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 15 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 06 2015 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 30,000 | 0 | 80,000 | 50 K to 80 K (+60.00 %) |
Jan 06 2015 | GYHT | HALOZYME THERAPEUT ... | Countouriotis Athena | SVP and Chief Medic ... | Option Exercise | A | 0.00 | 30,000 | 0 | 30,000 | |
Jan 06 2015 | GYHT | HALOZYME THERAPEUT ... | Countouriotis Athena | SVP and Chief Medic ... | Option Exercise | A | 9.99 | 250,000 | 2,497,500 | 250,000 | |
Dec 22 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | M | 0.00 | 17,625 | 0 | 42,594 | |
Dec 22 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Payment of Exercise | F | 9.46 | 6,621 | 62,635 | 354,554 | 361.2 K to 354.6 K (-1.83 %) |
Dec 22 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Buy | M | 0.00 | 17,625 | 0 | 361,175 | 343.6 K to 361.2 K (+5.13 %) |
Dec 01 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | M | 2.02 | 20,058 | 40,517 | 0 | |
Dec 01 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Buy | M | 2.02 | 20,058 | 40,517 | 343,550 | 323.5 K to 343.6 K (+6.20 %) |
Sep 16 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | M | 2.05 | 50,000 | 102,500 | 0 | |
Sep 16 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Buy | P | 8.90 | 25,000 | 222,500 | 323,492 | 298.5 K to 323.5 K (+8.38 %) |
Sep 16 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Buy | M | 2.05 | 50,000 | 102,500 | 298,492 | 248.5 K to 298.5 K (+20.12 %) |
Sep 16 2014 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | P | 8.92 | 50,000 | 446,000 | 50,000 | 0 to 50 K |
Aug 21 2014 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Option Exercise | M | 2.05 | 75,000 | 153,750 | 0 | |
Aug 21 2014 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Sell | S | 9.96 | 75,000 | 746,985 | 179,876 | 254.9 K to 179.9 K (-29.43 %) |
Aug 21 2014 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Buy | M | 2.05 | 75,000 | 153,750 | 254,876 | 179.9 K to 254.9 K (+41.70 %) |
Aug 18 2014 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Option Exercise | M | 2.05 | 75,000 | 153,750 | 0 | |
Aug 18 2014 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Sell | S | 9.96 | 35,000 | 348,726 | 273,176 | 308.2 K to 273.2 K (-11.36 %) |
Aug 18 2014 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Buy | M | 2.05 | 75,000 | 153,750 | 308,176 | 233.2 K to 308.2 K (+32.16 %) |
May 16 2014 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Option Exercise | M | 4.10 | 150,000 | 615,000 | 0 | |
May 16 2014 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Sell | S | 7.56 | 126,700 | 957,991 | 233,176 | 359.9 K to 233.2 K (-35.21 %) |
May 16 2014 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Buy | M | 4.10 | 150,000 | 615,000 | 359,876 | 209.9 K to 359.9 K (+71.47 %) |
May 15 2014 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 24,876 | 0 | 3,504,876 | 3.5 M to 3.5 M (+0.71 %) |
May 14 2014 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Grant | A | 0.00 | 24,876 | 0 | 179,876 | 155 K to 179.9 K (+16.05 %) |
May 14 2014 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 24,876 | 0 | 169,876 | 145 K to 169.9 K (+17.16 %) |
May 14 2014 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 24,876 | 0 | 304,876 | 280 K to 304.9 K (+8.88 %) |
May 14 2014 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 0.00 | 24,876 | 0 | 194,876 | 170 K to 194.9 K (+14.63 %) |
May 14 2014 | GYHT | HALOZYME THERAPEUT ... | Posard Matthew L. | Director | Grant | A | 0.00 | 24,876 | 0 | 44,876 | 20 K to 44.9 K (+124.38 %) |
May 14 2014 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Grant | A | 0.00 | 24,876 | 0 | 209,876 | 185 K to 209.9 K (+13.45 %) |
Feb 10 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | A | 0.00 | 31,500 | 0 | 31,500 | |
Feb 10 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | A | 13.10 | 50,000 | 655,000 | 50,000 | |
Feb 10 2014 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Option Exercise | A | 0.00 | 31,500 | 0 | 31,500 | |
Feb 10 2014 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Option Exercise | A | 13.10 | 50,000 | 655,000 | 50,000 | |
Feb 10 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | A | 0.00 | 28,350 | 0 | 28,350 | |
Feb 10 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | A | 13.10 | 45,000 | 589,500 | 45,000 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Option Exercise | M | 0.00 | 7,500 | 0 | 22,500 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Option Exercise | M | 0.00 | 13,889 | 0 | 41,667 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Buy | M | 0.00 | 4,682 | 0 | 20,869 | 16.2 K to 20.9 K (+28.92 %) |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Buy | M | 0.00 | 8,360 | 0 | 16,187 | 7.8 K to 16.2 K (+106.81 %) |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | M | 0.00 | 7,500 | 0 | 22,500 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | M | 0.00 | 2,084 | 0 | 4,166 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | M | 0.00 | 16,204 | 0 | 48,612 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Buy | M | 0.00 | 4,864 | 0 | 54,025 | 49.2 K to 54 K (+9.89 %) |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Buy | M | 0.00 | 1,242 | 0 | 49,161 | 47.9 K to 49.2 K (+2.59 %) |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Buy | M | 0.00 | 10,387 | 0 | 47,919 | 37.5 K to 47.9 K (+27.68 %) |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | M | 0.00 | 2,213 | 0 | 6,637 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | M | 0.00 | 3,125 | 0 | 6,250 | |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Buy | M | 0.00 | 2,213 | 0 | 248,492 | 246.3 K to 248.5 K (+0.90 %) |
Feb 04 2014 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Buy | M | 0.00 | 3,125 | 0 | 246,279 | 243.2 K to 246.3 K (+1.29 %) |
Jan 08 2014 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | A | 0.00 | 120,000 | 0 | 120,000 | |
Jan 08 2014 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | A | 14.66 | 700,000 | 10,262,000 | 700,000 | |
Dec 23 2013 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP, Chief Financial ... | Option Exercise | M | 0.00 | 10,281 | 0 | 60,219 | |
Dec 23 2013 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP, Chief Financial ... | Buy | M | 0.00 | 6,419 | 0 | 243,154 | 236.7 K to 243.2 K (+2.71 %) |
Dec 11 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | M | 2.02 | 10,420 | 21,048 | 34,864 | |
Dec 11 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | M | 2.05 | 33,113 | 67,882 | 667 | |
Dec 11 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | M | 2.02 | 6,467 | 13,063 | 0 | |
Dec 11 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | M | 2.05 | 33,113 | 67,882 | 3,641,380 | 3.6 M to 3.6 M (+0.92 %) |
Dec 11 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | M | 2.02 | 6,467 | 13,063 | 3,608,267 | 3.6 M to 3.6 M (+0.18 %) |
Dec 11 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | M | 2.02 | 10,420 | 21,048 | 3,601,800 | 3.6 M to 3.6 M (+0.29 %) |
Oct 16 2013 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | X | 4.94 | 10,000 | 49,400 | 0 | |
Oct 16 2013 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | X | 4.94 | 10,000 | 49,400 | 3,480,000 | 3.5 M to 3.5 M (+0.29 %) |
Sep 16 2013 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Option Exercise | M | 0.39 | 100,000 | 39,000 | 0 | |
Sep 16 2013 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Sell | S | 9.16 | 37,500 | 343,680 | 155,000 | 192.5 K to 155 K (-19.48 %) |
Sep 16 2013 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Sell | S | 9.10 | 37,500 | 341,359 | 192,500 | 230 K to 192.5 K (-16.30 %) |
Sep 16 2013 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Buy | M | 0.39 | 100,000 | 39,000 | 230,000 | 130 K to 230 K (+76.92 %) |
Sep 16 2013 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | M | 0.39 | 130,000 | 50,700 | 0 | |
Sep 16 2013 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Buy | M | 0.39 | 130,000 | 50,700 | 236,735 | 106.7 K to 236.7 K (+121.80 %) |
Sep 11 2013 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Sell | S | 7.11 | 10,000 | 71,091 | 13,198 | 23.2 K to 13.2 K (-43.11 %) |
Aug 14 2013 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Buy | P | 6.91 | 50,000 | 345,710 | 280,000 | 230 K to 280 K (+21.74 %) |
Aug 14 2013 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Buy | P | 6.72 | 50,000 | 335,935 | 230,000 | 180 K to 230 K (+27.78 %) |
Aug 14 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | M | 2.05 | 20,000 | 41,000 | 40,000 | |
Aug 14 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | M | 2.05 | 20,000 | 41,000 | 3,591,380 | 3.6 M to 3.6 M (+0.56 %) |
May 20 2013 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,470,000 | 3.5 M to 3.5 M (+0.58 %) |
May 24 2013 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | A | 0.00 | 70,500 | 0 | 70,500 | |
May 24 2013 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | VP and Chief Financ ... | Option Exercise | A | 7.17 | 117,500 | 842,475 | 117,500 | |
May 16 2013 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 20,000 | 0 | 180,000 | 160 K to 180 K (+12.50 %) |
May 16 2013 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 0.00 | 20,000 | 0 | 170,000 | 150 K to 170 K (+13.33 %) |
May 16 2013 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Grant | A | 0.00 | 20,000 | 0 | 185,000 | 165 K to 185 K (+12.12 %) |
May 16 2013 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 20,000 | 0 | 145,000 | 125 K to 145 K (+16.00 %) |
May 16 2013 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Grant | A | 0.00 | 20,000 | 0 | 130,000 | 110 K to 130 K (+18.18 %) |
Mar 28 2013 | GYHT | HALOZYME THERAPEUT ... | Posard Matthew L. | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Option Exercise | A | 0.00 | 27,000 | 0 | 27,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Option Exercise | A | 6.55 | 45,000 | 294,750 | 45,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | A | 0.00 | 30,000 | 0 | 30,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | A | 6.55 | 50,000 | 327,500 | 50,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Option Exercise | A | 0.00 | 30,000 | 0 | 30,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Option Exercise | A | 6.55 | 50,000 | 327,500 | 50,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | A | 0.00 | 39,000 | 0 | 39,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | A | 6.55 | 65,000 | 425,750 | 65,000 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Option Exercise | A | 0.00 | 37,200 | 0 | 37,200 | |
Feb 06 2013 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Option Exercise | A | 6.55 | 62,000 | 406,100 | 62,000 | |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | M | 0.00 | 4,737 | 0 | 3,571,380 | 3.6 M to 3.6 M (+0.13 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | M | 0.00 | 11,312 | 0 | 3,566,643 | 3.6 M to 3.6 M (+0.32 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Buy | M | 0.00 | 1,239 | 0 | 37,532 | 36.3 K to 37.5 K (+3.41 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Buy | M | 0.00 | 9,993 | 0 | 36,293 | 26.3 K to 36.3 K (+38.00 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Buy | M | 0.00 | 3,508 | 0 | 23,198 | 19.7 K to 23.2 K (+17.82 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Buy | M | 0.00 | 8,290 | 0 | 19,690 | 11.4 K to 19.7 K (+72.72 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Buy | M | 0.00 | 3,958 | 0 | 35,667 | 31.7 K to 35.7 K (+12.48 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Buy | M | 0.00 | 8,509 | 0 | 31,709 | 23.2 K to 31.7 K (+36.68 %) |
Feb 05 2013 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Buy | M | 0.00 | 7,827 | 0 | 7,827 | 0 to 7.8 K |
Nov 29 2012 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Buy | P | 5.57 | 15,000 | 83,550 | 165,000 | 150 K to 165 K (+10.00 %) |
Nov 14 2012 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Buy | P | 5.21 | 50,000 | 260,500 | 160,000 | 110 K to 160 K (+45.45 %) |
Nov 14 2012 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Buy | P | 5.22 | 20,000 | 104,400 | 26,300 | 6.3 K to 26.3 K (+317.46 %) |
Aug 28 2012 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Buy | P | 5.70 | 20,000 | 113,974 | 150,000 | 130 K to 150 K (+15.38 %) |
Aug 14 2012 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | P | 5.50 | 2,000 | 11,000 | 3,555,331 | 3.6 M to 3.6 M (+0.06 %) |
Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.48 | 2,731 | 20,428 | 331,394 | 328.7 K to 331.4 K (+0.83 %) |
Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.48 | 2,732 | 20,435 | 331,395 | 328.7 K to 331.4 K (+0.83 %) |
Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.37 | 44,823 | 330,346 | 328,663 | 283.8 K to 328.7 K (+15.79 %) |
Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.37 | 44,823 | 330,346 | 328,663 | 283.8 K to 328.7 K (+15.79 %) |
Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.39 | 49,540 | 366,101 | 283,840 | 234.3 K to 283.8 K (+21.14 %) |
Jun 05 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.39 | 49,540 | 366,101 | 283,840 | 234.3 K to 283.8 K (+21.14 %) |
May 17 2012 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | M | 0.00 | 16,465 | 0 | 3,553,331 | 3.5 M to 3.6 M (+0.47 %) |
May 17 2012 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Buy | M | 0.00 | 11,400 | 0 | 11,400 | 0 to 11.4 K |
May 17 2012 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Buy | M | 0.00 | 15,200 | 0 | 23,200 | 8 K to 23.2 K (+190.00 %) |
May 16 2012 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Buy | P | 7.49 | 20,000 | 149,800 | 130,000 | 110 K to 130 K (+18.18 %) |
May 17 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.50 | 299,007 | 2,242,553 | 3,977,445 | 3.7 M to 4 M (+8.13 %) |
May 17 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.44 | 344,910 | 2,566,130 | 3,678,438 | 3.3 M to 3.7 M (+10.35 %) |
May 17 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 7.35 | 427,581 | 3,142,720 | 3,333,528 | 2.9 M to 3.3 M (+14.71 %) |
May 07 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,450,000 | 3.4 M to 3.5 M (+0.58 %) |
May 04 2012 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 20,000 | 0 | 125,000 | 105 K to 125 K (+19.05 %) |
May 04 2012 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Grant | A | 0.00 | 20,000 | 0 | 110,000 | 90 K to 110 K (+22.22 %) |
May 04 2012 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 0.00 | 20,000 | 0 | 110,000 | 90 K to 110 K (+22.22 %) |
May 04 2012 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 20,000 | 0 | 110,000 | 90 K to 110 K (+22.22 %) |
May 04 2012 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Grant | A | 0.00 | 20,000 | 0 | 150,000 | 130 K to 150 K (+15.38 %) |
Feb 13 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 10.61 | 185,000 | 1,962,850 | 234,300 | 49.3 K to 234.3 K (+375.25 %) |
Feb 13 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 10.61 | 185,000 | 1,962,850 | 234,300 | 49.3 K to 234.3 K (+375.25 %) |
Feb 13 2012 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 10.61 | 990,000 | 10,503,900 | 2,905,947 | 1.9 M to 2.9 M (+51.67 %) |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | A | 0.00 | 81,019 | 0 | 89,353 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | A | 0.00 | 8,334 | 0 | 8,334 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Shaffer James P | VP & Chief Commerci ... | Option Exercise | A | 11.29 | 16,667 | 188,170 | 16,667 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | LIU JEAN I | VP & General Counse ... | Option Exercise | A | 0.00 | 69,444 | 0 | 69,444 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | VP, Chief Financial ... | Option Exercise | A | 0.00 | 74,271 | 0 | 74,271 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | VP, Chief Financial ... | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | VP, Chief Financial ... | Option Exercise | A | 11.29 | 50,000 | 564,500 | 50,000 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | A | 0.00 | 96,065 | 0 | 96,065 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | A | 0.00 | 30,000 | 0 | 30,000 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Option Exercise | A | 11.29 | 60,000 | 677,400 | 60,000 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP & Chief Scientif ... | Option Exercise | A | 0.00 | 69,444 | 0 | 69,444 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP & Chief Scientif ... | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
Feb 06 2012 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP & Chief Scientif ... | Option Exercise | A | 11.29 | 50,000 | 564,500 | 50,000 | |
Nov 23 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.00 | 166,100 | 1,328,800 | 1,915,947 | 1.7 M to 1.9 M (+9.49 %) |
Nov 23 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.11 | 55,146 | 447,234 | 1,749,847 | 1.7 M to 1.7 M (+3.25 %) |
Nov 23 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.04 | 56,477 | 454,075 | 1,694,701 | 1.6 M to 1.7 M (+3.45 %) |
Nov 16 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.19 | 175,520 | 1,437,509 | 1,638,224 | 1.5 M to 1.6 M (+12.00 %) |
Nov 16 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.18 | 242,704 | 1,985,319 | 1,462,704 | 1.2 M to 1.5 M (+19.89 %) |
Nov 16 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.13 | 220,000 | 1,788,600 | 1,220,000 | 1000 K to 1.2 M (+22.00 %) |
Nov 15 2011 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Buy | P | 8.15 | 5,000 | 40,750 | 130,000 | 125 K to 130 K (+4.00 %) |
Aug 10 2011 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Buy | P | 5.88 | 8,000 | 47,010 | 8,000 | 0 to 8 K |
Aug 11 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.13 | 261,669 | 1,604,031 | 1,000,000 | 738.3 K to 1000 K (+35.44 %) |
Aug 11 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.88 | 738,331 | 4,341,386 | 738,331 | 0 to 738.3 K |
Aug 10 2011 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | CEO, President | Buy | P | 5.84 | 6,000 | 35,040 | 3,536,866 | 3.5 M to 3.5 M (+0.17 %) |